A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management
Sponsor: Sinew Pharma Inc.
Listed as NCT05842733, this PHASE2 trial focuses on Pain, Postoperative and remains ongoing. Sponsored by Sinew Pharma Inc., it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Unknown PHASE2
Status: Enrolling By Invitation → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Enrolling By Invitation PHASE2
▶ Show 1 earlier version
-
Jun 2023 — Aug 2023 [monthly]
Enrolling By Invitation PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sinew Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .